South Korea · Delayed Price · Currency is KRW Kyung Nam Pharm Statistics
Total Valuation
Kyung Nam Pharm has a market cap or net worth of KRW 34.23 billion. The enterprise value is 35.14 billion.
| Market Cap | 34.23B |
| Enterprise Value | 35.14B |
Important Dates
The last earnings date was Monday, March 30, 2026.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kyung Nam Pharm has 15.63 million shares outstanding.
| Current Share Class | 15.63M |
| Shares Outstanding | 15.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +16.51% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 8.51M |
Valuation Ratios
The trailing PE ratio is 3.56.
| PE Ratio | 3.56 |
| Forward PE | n/a |
| PS Ratio | 0.61 |
| PB Ratio | 0.30 |
| P/TBV Ratio | 0.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 56.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.91, with an EV/FCF ratio of -5.35.
| EV / Earnings | 3.66 |
| EV / Sales | 0.63 |
| EV / EBITDA | 12.91 |
| EV / EBIT | 52.83 |
| EV / FCF | -5.35 |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.76 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 13.37 |
| Debt / FCF | -5.44 |
| Interest Coverage | 0.48 |
Financial Efficiency
Return on equity (ROE) is -3.29% and return on invested capital (ROIC) is 0.59%.
| Return on Equity (ROE) | -3.29% |
| Return on Assets (ROA) | 0.24% |
| Return on Invested Capital (ROIC) | 0.59% |
| Return on Capital Employed (ROCE) | 0.51% |
| Weighted Average Cost of Capital (WACC) | 4.45% |
| Revenue Per Employee | 231.21M |
| Profits Per Employee | 39.54M |
| Employee Count | 243 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 3.11 |
Taxes
In the past 12 months, Kyung Nam Pharm has paid 676.63 million in taxes.
| Income Tax | 676.63M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.92% in the last 52 weeks. The beta is 0.11, so Kyung Nam Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -34.92% |
| 50-Day Moving Average | 3,479.20 |
| 200-Day Moving Average | 3,351.60 |
| Relative Strength Index (RSI) | 23.44 |
| Average Volume (20 Days) | 243,786 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kyung Nam Pharm had revenue of KRW 56.18 billion and earned 9.61 billion in profits. Earnings per share was 308.12.
| Revenue | 56.18B |
| Gross Profit | 15.52B |
| Operating Income | 613.15M |
| Pretax Income | -2.62B |
| Net Income | 9.61B |
| EBITDA | 2.67B |
| EBIT | 613.15M |
| Earnings Per Share (EPS) | 308.12 |
Balance Sheet
The company has 44.41 billion in cash and 35.71 billion in debt, with a net cash position of 8.70 billion or 556.94 per share.
| Cash & Cash Equivalents | 44.41B |
| Total Debt | 35.71B |
| Net Cash | 8.70B |
| Net Cash Per Share | 556.94 |
| Equity (Book Value) | 113.49B |
| Book Value Per Share | 7,261.33 |
| Working Capital | 31.14B |
Cash Flow
In the last 12 months, operating cash flow was 600.88 million and capital expenditures -7.17 billion, giving a free cash flow of -6.56 billion.
| Operating Cash Flow | 600.88M |
| Capital Expenditures | -7.17B |
| Depreciation & Amortization | 2.06B |
| Net Borrowing | -4.80B |
| Free Cash Flow | -6.56B |
| FCF Per Share | -420.03 |
Margins
Gross margin is 27.62%, with operating and profit margins of 1.09% and 17.10%.
| Gross Margin | 27.62% |
| Operating Margin | 1.09% |
| Pretax Margin | -4.67% |
| Profit Margin | 17.10% |
| EBITDA Margin | 4.75% |
| EBIT Margin | 1.09% |
| FCF Margin | n/a |
Dividends & Yields
Kyung Nam Pharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -52.38% |
| Shareholder Yield | -52.38% |
| Earnings Yield | 28.07% |
| FCF Yield | -19.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 14, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Apr 14, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Kyung Nam Pharm has an Altman Z-Score of 0.96 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.96 |
| Piotroski F-Score | 5 |